Which has stronger earnings and valuation, ALXO or ANVS?

ALX Oncology is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.49 N/A Annovis Bio N/A N/A -$28.85M -$1.71 N/A

Is ALXO or ANVS more profitable?

ALX Oncology's return on equity of -124.06% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -124.06% -85.57% Annovis Bio N/A -318.08% -215.47%

Does the media prefer ALXO or ANVS?

In the previous week, ALX Oncology had 2 more articles in the media than Annovis Bio. MarketBeat recorded 4 mentions for ALX Oncology and 2 mentions for Annovis Bio. ALX Oncology's average media sentiment score of 0.72 beat Annovis Bio's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ANVS or SRZN more profitable?

Annovis Bio has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Annovis Bio's return on equity of -318.08% beat Surrozen's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -318.08% -215.47% Surrozen -4,810.50% -4,055.04% -154.08%

Is ANVS or AMRN more profitable?

Annovis Bio has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -318.08% -215.47% Amarin -15.51% -2.99% -2.07%

Does the media refer more to ANVS or AMRN?

In the previous week, Amarin had 2 more articles in the media than Annovis Bio. MarketBeat recorded 4 mentions for Amarin and 2 mentions for Annovis Bio. Amarin's average media sentiment score of 0.95 beat Annovis Bio's score of 0.00 indicating that Amarin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amarin 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ELDN or ANVS?

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eledon Pharmaceuticals N/A N/A -$45.62M -$0.77 N/A Annovis Bio N/A N/A -$28.85M -$1.71 N/A

Is ELDN or ANVS more profitable?

Eledon Pharmaceuticals' return on equity of -116.97% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -116.97% -41.91% Annovis Bio N/A -318.08% -215.47%

Which has higher valuation and earnings, FBRX or ANVS?

Forte Biosciences is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.64 N/A Annovis Bio N/A N/A -$28.85M -$1.71 N/A

Is FBRX or ANVS more profitable?

Forte Biosciences' return on equity of -106.17% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -106.17% -85.50% Annovis Bio N/A -318.08% -215.47%

Annovis Bio (ANVS) Competitors

$1.82 -0.10 (-4.95%)

Closing price 03:59 PM Eastern

Extended Trading

$1.82 0.00 (0.00%)

As of 05:07 PM Eastern

Compare

ANVS vs. ALXO, SRZN, AMRN, ELDN, and FBRX

Should you buy Annovis Bio stock or one of its competitors? MarketBeat compares Annovis Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Annovis Bio include ALX Oncology (ALXO), Surrozen (SRZN), Amarin (AMRN), Eledon Pharmaceuticals (ELDN), and Forte Biosciences (FBRX). These companies are all part of the "pharmaceutical products" industry.

How does Annovis Bio compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

ALX Oncology has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

ALX Oncology presently has a consensus target price of $4.60, suggesting a potential upside of 155.56%. Annovis Bio has a consensus target price of $13.50, suggesting a potential upside of 639.73%. Given Annovis Bio's higher possible upside, analysts plainly believe Annovis Bio is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

ALX Oncology is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 21.0% of ALX Oncology shares are held by company insiders. Comparatively, 20.8% of Annovis Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, ALX Oncology had 2 more articles in the media than Annovis Bio. MarketBeat recorded 4 mentions for ALX Oncology and 2 mentions for Annovis Bio. ALX Oncology's average media sentiment score of 0.72 beat Annovis Bio's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ALX Oncology's return on equity of -124.06% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Annovis Bio	N/A	-318.08%	-215.47%

Summary

ALX Oncology beats Annovis Bio on 9 of the 13 factors compared between the two stocks.

How does Annovis Bio compare to Surrozen?

Annovis Bio (NYSE:ANVS) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Annovis Bio currently has a consensus target price of $13.50, indicating a potential upside of 639.73%. Surrozen has a consensus target price of $42.00, indicating a potential upside of 69.97%. Given Annovis Bio's higher possible upside, equities analysts clearly believe Annovis Bio is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by insiders. Comparatively, 31.7% of Surrozen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Annovis Bio has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

Annovis Bio has higher earnings, but lower revenue than Surrozen. Annovis Bio is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
Surrozen	$3.48M	82.44	-$242.03M	-$37.59	N/A

In the previous week, Annovis Bio had 1 more articles in the media than Surrozen. MarketBeat recorded 2 mentions for Annovis Bio and 1 mentions for Surrozen. Surrozen's average media sentiment score of 1.87 beat Annovis Bio's score of 0.00 indicating that Surrozen is being referred to more favorably in the news media.

Company	Overall Sentiment
Annovis Bio	Neutral
Surrozen	Very Positive

Annovis Bio has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Annovis Bio's return on equity of -318.08% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
Surrozen	-4,810.50%	-4,055.04%	-154.08%

Summary

Surrozen beats Annovis Bio on 9 of the 16 factors compared between the two stocks.

How does Annovis Bio compare to Amarin?

Annovis Bio (NYSE:ANVS) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 20.8% of Annovis Bio shares are held by insiders. Comparatively, 4.2% of Amarin shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Amarin had 2 more articles in the media than Annovis Bio. MarketBeat recorded 4 mentions for Amarin and 2 mentions for Annovis Bio. Amarin's average media sentiment score of 0.95 beat Annovis Bio's score of 0.00 indicating that Amarin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amarin	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annovis Bio has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
Amarin	-15.51%	-2.99%	-2.07%

Annovis Bio has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
Amarin	$213.65M	1.41	-$38.80M	-$0.65	N/A

Annovis Bio has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Amarin has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market.

Annovis Bio currently has a consensus target price of $13.50, suggesting a potential upside of 639.73%. Amarin has a consensus target price of $12.00, suggesting a potential downside of 16.43%. Given Annovis Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Annovis Bio is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Summary

Annovis Bio beats Amarin on 8 of the 15 factors compared between the two stocks.

How does Annovis Bio compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Eledon Pharmaceuticals' return on equity of -116.97% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Annovis Bio	N/A	-318.08%	-215.47%

Eledon Pharmaceuticals has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 12.3% of Eledon Pharmaceuticals shares are owned by insiders. Comparatively, 20.8% of Annovis Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Eledon Pharmaceuticals presently has a consensus target price of $9.67, indicating a potential upside of 157.09%. Annovis Bio has a consensus target price of $13.50, indicating a potential upside of 639.73%. Given Annovis Bio's higher possible upside, analysts plainly believe Annovis Bio is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

In the previous week, Eledon Pharmaceuticals had 3 more articles in the media than Annovis Bio. MarketBeat recorded 5 mentions for Eledon Pharmaceuticals and 2 mentions for Annovis Bio. Eledon Pharmaceuticals' average media sentiment score of 1.17 beat Annovis Bio's score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eledon Pharmaceuticals	Positive
Annovis Bio	Neutral

Summary

Eledon Pharmaceuticals beats Annovis Bio on 8 of the 13 factors compared between the two stocks.

How does Annovis Bio compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

In the previous week, Annovis Bio had 1 more articles in the media than Forte Biosciences. MarketBeat recorded 2 mentions for Annovis Bio and 1 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 1.87 beat Annovis Bio's score of 0.00 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Forte Biosciences	Very Positive
Annovis Bio	Neutral

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by company insiders. Comparatively, 20.8% of Annovis Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Forte Biosciences is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

Forte Biosciences' return on equity of -106.17% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
Annovis Bio	N/A	-318.08%	-215.47%

Forte Biosciences has a beta of 2.87, meaning that its share price is 187% more volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Forte Biosciences currently has a consensus target price of $67.00, indicating a potential upside of 248.23%. Annovis Bio has a consensus target price of $13.50, indicating a potential upside of 639.73%. Given Annovis Bio's higher probable upside, analysts plainly believe Annovis Bio is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Forte Biosciences beats Annovis Bio on 7 of the 13 factors compared between the two stocks.

Get Annovis Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANVS vs. The Competition

Export

Metric	Annovis Bio	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$63.24M	$3.32B	$6.31B	$23.23B
Dividend Yield	N/A	2.28%	2.68%	4.09%
P/E Ratio	-1.07	18.10	21.13	30.90
Price / Sales	N/A	327.47	546.80	24.79
Price / Cash	N/A	54.19	27.44	19.43
Price / Book	2.85	6.85	9.95	4.72
Net Income	-$28.85M	$24.15M	$3.56B	$1.07B
7 Day Performance	-18.71%	2.03%	2.15%	1.38%
1 Month Performance	N/A	N/A	N/A	0.51%
1 Year Performance	-22.01%	63.17%	36.47%	27.95%

Annovis Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANVS Annovis Bio	2.1456 of 5 stars	$1.83 -4.9%	$13.50 +639.7%	-17.7%	$63.24M	N/A	N/A	3	High Trading Volume
ALXO ALX Oncology	3.855 of 5 stars	$1.98 flat	$4.60 +132.3%	+291.1%	$266.43M	N/A	N/A	40	News Coverage Short Interest Decrease
SRZN Surrozen	4.0254 of 5 stars	$26.37 flat	$42.00 +59.3%	+208.4%	$306.16M	$3.48M	N/A	80	Positive News
AMRN Amarin	1.4252 of 5 stars	$14.43 flat	$12.00 -16.8%	+24.9%	$302.58M	$213.65M	N/A	360
ELDN Eledon Pharmaceuticals	2.6493 of 5 stars	$3.89 flat	$9.67 +148.5%	+26.2%	$300.26M	N/A	N/A	10	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ANVS) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Annovis Bio (ANVS) Competitors

ANVS vs. ALXO, SRZN, AMRN, ELDN, and FBRX

How does Annovis Bio compare to ALX Oncology?

Summary

How does Annovis Bio compare to Surrozen?

Summary

How does Annovis Bio compare to Amarin?

Summary

How does Annovis Bio compare to Eledon Pharmaceuticals?

Summary

How does Annovis Bio compare to Forte Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS vs. The Competition

Annovis Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Annovis Bio (ANVS) Competitors

ANVS vs. ALXO, SRZN, AMRN, ELDN, and FBRX

How does Annovis Bio compare to ALX Oncology?

Which has more risk & volatility, ALXO or ANVS?

Do analysts prefer ALXO or ANVS?

Which has stronger earnings and valuation, ALXO or ANVS?

Do insiders and institutionals hold more shares of ALXO or ANVS?

Does the media prefer ALXO or ANVS?

Is ALXO or ANVS more profitable?

Summary

How does Annovis Bio compare to Surrozen?

Do analysts recommend ANVS or SRZN?

Do institutionals & insiders believe in ANVS or SRZN?

Which has more volatility and risk, ANVS or SRZN?

Which has preferable valuation and earnings, ANVS or SRZN?

Does the media refer more to ANVS or SRZN?

Is ANVS or SRZN more profitable?

Summary

How does Annovis Bio compare to Amarin?

Do institutionals and insiders have more ownership in ANVS or AMRN?

Does the media refer more to ANVS or AMRN?

Is ANVS or AMRN more profitable?

Which has stronger valuation & earnings, ANVS or AMRN?

Which has more volatility and risk, ANVS or AMRN?

Do analysts rate ANVS or AMRN?

Summary

How does Annovis Bio compare to Eledon Pharmaceuticals?

Is ELDN or ANVS more profitable?

Which has more volatility and risk, ELDN or ANVS?

Do institutionals & insiders believe in ELDN or ANVS?

Do analysts prefer ELDN or ANVS?

Which has preferable valuation and earnings, ELDN or ANVS?

Does the media prefer ELDN or ANVS?

Summary

How does Annovis Bio compare to Forte Biosciences?

Does the media favor FBRX or ANVS?

Do insiders and institutionals believe in FBRX or ANVS?

Which has higher valuation and earnings, FBRX or ANVS?

Is FBRX or ANVS more profitable?

Which has more volatility and risk, FBRX or ANVS?

Do analysts rate FBRX or ANVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS vs. The Competition

Annovis Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools